Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Scios Final Analysis Of Natrecor Trial Finds Two Additional Deaths

This article was originally published in The Pink Sheet Daily

Executive Summary

Johnson & Johnson subsidiary maintains the additional deaths have “no impact on overall risk/benefit profile” of the heart failure therapy.

You may also be interested in...

Scios Natrecor Expanded Mortality Analysis Finds Two New Patient Deaths

The J&J subsidiary says the deaths have “no impact on the overall benefit/risk profile” of the heart failure drug when it is prescribed as labeled.

J&J/Scios Natrecor Labeling Change Includes Expanded Mortality Analysis

FDA does not believe a "Dear Doctor" letter or advisory committee review are warranted at this time. The new labeling reports 30-day and 180-day mortality risks for Natrecor compared to active controls in all randomized trials of the CHF therapy.

Natrecor Safety Labeling Change Likely, J&J Says

The company is in discussions with FDA to “ensure that correct conclusions are in label.” Adverse publicity from Circulation article questioning kidney safety of CHF drug is having an impact; mortality analysis in JAMA will raise more questions.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts